Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lineage Cell Therapeutics Inc
(NY:
LCTX
)
0.6000
-0.0414 (-6.45%)
Official Closing Price
Updated: 8:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Lineage Cell Therapeutics Inc
< Previous
1
2
3
Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 20, 2024
Via
Benzinga
Lineage Cell Therapeutics's Earnings Outlook
November 13, 2024
Via
Benzinga
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024
May 09, 2024
LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 07, 2024
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Lineage Cell Therapeutics: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
A Preview Of Lineage Cell Therapeutics's Earnings
March 06, 2024
Via
Benzinga
Lineage Cell Therapeutics: Q3 Earnings Insights
November 09, 2023
Via
Benzinga
Earnings Preview: Lineage Cell Therapeutics
November 08, 2023
Via
Benzinga
Lineage Cell Therapeutics Earnings Preview
August 09, 2023
Via
Benzinga
Earnings Scheduled For November 14, 2024
November 14, 2024
Via
Benzinga
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
Lineage Cell Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 01, 2024
Via
Benzinga
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
January 03, 2024
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 29, 2023
Via
Benzinga
Lineage Cell Therapeutics's Return On Capital Employed Overview
March 14, 2023
Via
Benzinga
Preview: Lineage Cell Therapeutics's Earnings
March 08, 2023
Via
Benzinga
3 Penny Stocks to Buy for the Next Bull Run
November 11, 2023
While penny stocks to buy represent a terribly risky venture, it’s possible that maybe one of these ideas could skyrocket.
Via
InvestorPlace
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
October 17, 2023
Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.
Via
InvestorPlace
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
September 06, 2023
Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and...
Via
Benzinga
Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
August 16, 2023
Gainers
Via
Benzinga
Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response
July 24, 2023
Lineage Cell Therapeutics Inc (NYSE: LCTX) and Cancer Research UK revealed primary and secondary endpoint results from the recently completed clinical study of VAC2 in advanced non-small
Via
Benzinga
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
April 13, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
3 Penny Stocks to Buy During Market Downturns
April 10, 2023
If you're looking for penny stocks to buy that can weather economic turmoil, these should make the cut due to their strong fundamentals.
Via
InvestorPlace
EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology
February 22, 2023
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive option and license agreement with Eterna Therapeutics Inc for beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell...
Via
Benzinga
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
January 25, 2023
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.
Via
Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.